Pluristem trial with NIH gives positive results for PLX-R18 on bone marrow radiation damage

20 February 2015

Israeli cell therapy specialist Pluristem Therapeutics (Nasdaq: PSTI) has announced the positive results of a recent trial by the US National Institutes of Health on PLX-R18 cells to treat bone marrow damaged by radiation exposure.

Injecting PLX-R18 cells into the muscle resulted in a significantly significant improvement in the recovery of white and red blood cell and platelet levels versus placebo, in animals exposed to high levels of radiation, such as those experienced after a nuclear disaster. The data also suggested that the treatment could shorten time to recovery.

Study observing efficacy of PLX-218 in mice

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK